Cargando…

IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer

PURPOSE: To compare participants’ knowledge about gene expression profiling (GEP) tests and recurrence risks after reading an information leaflet with that following viewing of an information film. METHODS: Using a randomised cross-over design, at time-point one (T1), women aged 45–75 years without...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallowfield, L. J., Farewell, D., Jones, H., May, S., Catt, S., Starkings, R., Jenkins, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750374/
https://www.ncbi.nlm.nih.gov/pubmed/34982321
http://dx.doi.org/10.1007/s10549-021-06491-2
_version_ 1784631445547909120
author Fallowfield, L. J.
Farewell, D.
Jones, H.
May, S.
Catt, S.
Starkings, R.
Jenkins, V.
author_facet Fallowfield, L. J.
Farewell, D.
Jones, H.
May, S.
Catt, S.
Starkings, R.
Jenkins, V.
author_sort Fallowfield, L. J.
collection PubMed
description PURPOSE: To compare participants’ knowledge about gene expression profiling (GEP) tests and recurrence risks after reading an information leaflet with that following viewing of an information film. METHODS: Using a randomised cross-over design, at time-point one (T1), women aged 45–75 years without breast cancer either read leaflets or watched information films about Oncotype DX or Prosigna tests. Participants answered nine questions assessing knowledge (maximum score 18). Next-day information in the opposite modality was provided and knowledge re-assessed. Additional questions probed which format was easiest to understand, participants’ preferences for film or leaflet and their reasons for these. RESULTS: 120 women participated (60 received OncotypeDX films and leaflets; 60 received the Prosigna versions). T1 mean knowledge scores were higher following film viewing (13.37) compared with that after reading leaflets (9.25) (mean difference 4.1; p < 0.0001; 95% CI 3.2, 5.0). When participants read leaflets first and subsequently viewed films, all increased their scores (mean + 6.08, from T1 of 9.25, p < 0.0001; 95% CI 5.44, 6.72). When films were viewed first, followed by leaflets, (36/60, 60%), participants’ scores declined (mean-1.55 from T1 of 13.37, p < 0.001; 95% CI -2.32, -0.78). A majority of participants expressed preferences for the films (88/120, 73.3%) irrespective as to whether they described OncotypeDX or Prosigna. Reasons included the clarity, ease of understanding, visual material and reassuring voice-over. CONCLUSION: Discussions between oncologists and patients about recurrence risk results can be challenging. Information leaflets may aid understanding but often employ complex language. Information films significantly improved knowledge and were preferred by participants.
format Online
Article
Text
id pubmed-8750374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87503742022-01-11 IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer Fallowfield, L. J. Farewell, D. Jones, H. May, S. Catt, S. Starkings, R. Jenkins, V. Breast Cancer Res Treat Preclinical Study PURPOSE: To compare participants’ knowledge about gene expression profiling (GEP) tests and recurrence risks after reading an information leaflet with that following viewing of an information film. METHODS: Using a randomised cross-over design, at time-point one (T1), women aged 45–75 years without breast cancer either read leaflets or watched information films about Oncotype DX or Prosigna tests. Participants answered nine questions assessing knowledge (maximum score 18). Next-day information in the opposite modality was provided and knowledge re-assessed. Additional questions probed which format was easiest to understand, participants’ preferences for film or leaflet and their reasons for these. RESULTS: 120 women participated (60 received OncotypeDX films and leaflets; 60 received the Prosigna versions). T1 mean knowledge scores were higher following film viewing (13.37) compared with that after reading leaflets (9.25) (mean difference 4.1; p < 0.0001; 95% CI 3.2, 5.0). When participants read leaflets first and subsequently viewed films, all increased their scores (mean + 6.08, from T1 of 9.25, p < 0.0001; 95% CI 5.44, 6.72). When films were viewed first, followed by leaflets, (36/60, 60%), participants’ scores declined (mean-1.55 from T1 of 13.37, p < 0.001; 95% CI -2.32, -0.78). A majority of participants expressed preferences for the films (88/120, 73.3%) irrespective as to whether they described OncotypeDX or Prosigna. Reasons included the clarity, ease of understanding, visual material and reassuring voice-over. CONCLUSION: Discussions between oncologists and patients about recurrence risk results can be challenging. Information leaflets may aid understanding but often employ complex language. Information films significantly improved knowledge and were preferred by participants. Springer US 2022-01-04 2022 /pmc/articles/PMC8750374/ /pubmed/34982321 http://dx.doi.org/10.1007/s10549-021-06491-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Preclinical Study
Fallowfield, L. J.
Farewell, D.
Jones, H.
May, S.
Catt, S.
Starkings, R.
Jenkins, V.
IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title_full IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title_fullStr IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title_full_unstemmed IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title_short IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
title_sort imparter, phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750374/
https://www.ncbi.nlm.nih.gov/pubmed/34982321
http://dx.doi.org/10.1007/s10549-021-06491-2
work_keys_str_mv AT fallowfieldlj imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT farewelld imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT jonesh imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT mays imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT catts imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT starkingsr imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer
AT jenkinsv imparterphase1ofaninterventiontoimprovepatientsunderstandingofgeneexpressionprofilingtestsinbreastcancer